Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo

Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathways

(2019) Zuoxing Wu et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Use of oral bisphosphonates and risk of hospital admission with osteonecrosis of the jaw: Large prospective cohort study in UK women

(2019) Clare J. Wotton et al.   BONE

Therapeutic Potential of the Rhizomes of Anemarrhena asphodeloides and Timosaponin A-III in an Animal Model of Lipopolysaccharide-Induced Lung Inflammation

(2018) Byung Kyu Park et al.   Biomolecules & Therapeutics

Inhibition effects of a natural inhibitor on RANKL downstream cellular signalling cascades cross-talking

(2018) Biao Wang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Oxymatrine exerts protective effects on osteoarthritis via modulating chondrocyte homoeostasis and suppressing osteoclastogenesis

(2018) Yafei Jiang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Atypical Femur Fractures – Review of epidemiology, relationship to bisphosphonates, prevention and clinical management

(2018) Dennis M Black et al.   ENDOCRINE REVIEWS

Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice

(2018) Mahesh Sapkota et al.   FOOD AND CHEMICAL TOXICOLOGY

Deguelin inhibits RANKL-induced osteoclastogenesis in vitro and prevents inflammation-mediated bone loss in vivo

(2018) Tan Zhang et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Tomatidine suppresses osteoclastogenesis and mitigates estrogen deficiency-induced bone mass loss by modulating TRAF6-mediated signaling

(2018) Bin Hu et al.   FASEB JOURNAL

Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis

(2018) Qingqing Wang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phosphatidyl inositol 3-kinase (PI3K)-mTOR inhibitor PKI-402 inhibits breast cancer induced osteolysis

(2018) Guixin Yuan et al.   CANCER LETTERS

Inhibition of titanium-particle-induced inflammatory osteolysis after local administration of dopamine and suppression of osteoclastogenesis via D2-like receptor signaling pathway

(2016) Huilin Yang et al.   BIOMATERIALS

Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balance

(2015) Su-Min Lim et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Sarsasapogenin induces apoptosis via the reactive oxygen species-mediated mitochondrial pathway and ER stress pathway in HeLa cells

(2013) Shuying Shen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Andrographolide suppresses RANKL-induced osteoclastogenesisin vitroand prevents inflammatory bone lossin vivo

(2013) Z J Zhai et al.   BRITISH JOURNAL OF PHARMACOLOGY

Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management

(2012) Kurt A. Kennel et al.   MAYO CLINIC PROCEEDINGS

Oestrogen deficiency modulates particle-induced osteolysis

(2011) Christophe Nich et al.   ARTHRITIS RESEARCH & THERAPY

RANKL-mediated Reactive Oxygen Species Pathway That Induces Long Lasting Ca2+Oscillations Essential for Osteoclastogenesis

(2010) Min Seuk Kim et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Bone development and inflammatory disease is regulated by AP-1 (Fos/Jun)

(2009) E F Wagner   ANNALS OF THE RHEUMATIC DISEASES

Osteoclasts are important for bone angiogenesis

(2009) F. C. Cackowski et al.   BLOOD

Osteoimmunology: Interactions of the Bone and Immune System

(2008) Joseph Lorenzo et al.   ENDOCRINE REVIEWS

NFATc1 Induces Osteoclast Fusion Via Up-Regulation of Atp6v0d2 and the Dendritic Cell-Specific Transmembrane Protein (DC-STAMP)

(2007) Kabsun Kim et al.   MOLECULAR ENDOCRINOLOGY